# EDGAR Filing Document

**Accession Number:** 0001712762
**File Stem:** 0001493152-26-020591
**Filing Date:** 2026-4
**Character Count:** 15173
**Document Hash:** 933f3d2f182cf6e17fb02c1240a135e0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-020591.hdr.sgml**: 20260430

**ACCESSION NUMBER**: 0001493152-26-020591

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20260430

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260430

**DATE AS OF CHANGE**: 20260430

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** bioAffinity Technologies, Inc.
- **CENTRAL INDEX KEY:** 0001712762
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 465211056
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41463
- **FILM NUMBER:** 26926106

**BUSINESS ADDRESS:**
- **STREET 1:** 3300 NACOGDOCHES ROAD
- **STREET 2:** SUITE 216
- **CITY:** SAN ANTONIO
- **STATE:** TX
- **ZIP:** 78217
- **BUSINESS PHONE:** 210-698-5334

**MAIL ADDRESS:**
- **STREET 1:** 3300 NACOGDOCHES ROAD
- **STREET 2:** SUITE 216
- **CITY:** SAN ANTONIO
- **STATE:** TX
- **ZIP:** 78217

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

**April 30, 2026**

Date of Report (Date of earliest event reported)

**bioAffinity Technologies, Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-41463** | **46-5211056** |
| (State or other jurisdiction<br> of incorporation) | (Commission<br> File Number) | (I.R.S. Employer<br> Identification Number) |

---

**3300 Nacogdoches Road**

**Suite 216**

**San Antonio, Texas 78257**

**(210) 698-5334**

(Address of principal executive offices and Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, par value $0.007 per share | BIAF | The Nasdaq Stock Market LLC |
| Tradeable Warrants to purchase Common Stock | BIAFW | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

At the 2026 Annual Meeting (as defined below) of bioAffinity Technologies, Inc. (the "Company"), stockholders approved an amendment to the Company's 2024 Equity Incentive Compensation Plan (the "2024 Plan") to increase the number of shares of common stock, par value $0.007 per share (the "Common Stock"), reserved for issuance thereunder to 1,000,000 from 66,666 shares (the "Plan Amendment").

The foregoing description of the Plan Amendment is qualified in its entirety by reference to the text of the Plan Amendment, a copy of which is attached as Exhibit 10.1 to this Current Report on Form 8-K.

**Item 5.07. Submission of Matters to a Vote of Security Holders.**

At the 2026 Annual Meeting of Stockholders (the "2026 Annual Meeting") of the Company held on April 30, 2026, the Company's stockholders voted on ten proposals, each of which is listed below and described in more detail in the Company's Definitive Proxy Statement, which was filed with the Securities and Exchange Commission on March 16, 2026. With respect to each proposal, holders of the Company's Common Stock were entitled to cast one vote per share of Common Stock held as of the close of business on the record date of March 13, 2026 (the "Record Date"). On the Record Date there were 4,498,675 shares of the Company's Common Stock issued and outstanding and entitled to vote at the 2026 Annual Meeting.

The following are the final results of voting on each of the proposals presented at the 2026 Annual Meeting:

***Proposal No. 1: Election of Directors***

The stockholders elected each of the six director nominees to serve on the Company's board of directors until the 2027 Annual Meeting of Stockholders and until such director's successor has been duly elected and qualified.

---

| | | | |
|:---|:---|:---|:---|
| **Nominee** | **Votes For** | **Votes Withheld** | **Broker Non-Votes** |
| Maria Zannes, JD | 409762 | 43895 | 1264352 |
| Steven Girgenti | 409803 | 43854 | 1264352 |
| Peter Knight | 409630 | 44027 | 1264352 |
| Jamie Platt, PhD | 412154 | 41503 | 1264352 |
| Roberto Rios | 409707 | 43950 | 1264352 |
| John J. Oppenheimer, MD | 409883 | 43774 | 1264352 |

---

***Proposal No. 2: Ratification of Appointment of Independent Registered Public Accounting Firm***

The stockholders ratified the appointment of WithumSmith+Brown, PC as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.

---

| | | | |
|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** | **Broker Non-Votes** |
| 1496349 | 90879 | 130781 |  |

---

***Proposal No. 3: Warrant Exercise Proposal***

The stockholders approved the issuance of up to an aggregate of 271,500 shares of Common Stock upon the exercise of (i) 223,831 shares of Common Stock issuable upon exercise of Common Stock purchase warrants issued in connection with the private placement offering that closed on August 14, 2025 (the "August 2025 Common Warrants"), (ii) 47,669 shares of Common Stock issuable upon exercise of Common Stock purchase warrants issued in connection with the warrant inducement transaction that closed on August 14, 2025 (the "August 2025 Inducement Warrants", together the August 2025 Common Warrants and the Inducement Warrants, the "August 2025 Warrants"), respectively, that may be equal to or exceed 20% of Common Stock outstanding before such offering.

---

| | | | |
|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** | **Broker Non-Votes** |
| 349023 | 96738 | 7896 | 1264352 |

---

***Proposal No. 4: Warrant Anti-Dilution Adjustment Proposal***

The stockholders approved an anti-dilution provision of the August 2025 Warrants and the reduction in the exercise price of the August 2025 Warrants (subject to a floor price of $4.50 per share) and corresponding increase in the number of shares issuable upon exercise thereof up to an aggregate maximum of 365,620 shares of Common Stock, resulting from the triggering of such anti-dilution provision.

---

| | | | |
|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** | **Broker Non-Votes** |
| 349847 | 96500 | 7310 | 1264352 |

---

***Proposal No. 5: Series B Anti-Dilution Adjustment Proposal***

The stockholders approved an anti-dilution provision of the Series B Preferred Stock and the reduction in the exercise price of the Series B Preferred Stock (subject to a floor price of $3.00 per share) and corresponding increase in the number of shares of Common Stock issuable upon conversion of the Series B Preferred Stock thereof up to an aggregate of 131,884 shares of Common Stock, resulting from the triggering of such anti-dilution provision.

---

| | | | |
|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** | **Broker Non-Votes** |
| 347609 | 98645 | 7403 | 1264352 |

---

***Proposal No. 6: Plan Amendment Proposal***

The stockholders approved an amendment to the 2024 Plan to increase the number of shares of Common Stock reserved for issuance thereunder to 1,000,000 shares from 66,666 shares.

---

| | | | |
|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** | **Broker Non-Votes** |
| 318231 | 131076 | 4350 | 1264352 |

---

***Proposal No. 7: Offering Proposal***

The stockholders authorized the issuance of securities in one or more non-public offerings in accordance with Nasdaq Marketplace Rule 5635(d).

---

| | | | |
|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** | **Broker Non-Votes** |
| 324423 | 123864 | 5370 | 1264352 |

---

***Proposal No. 8: Change of Control Proposal***

The stockholders approved any change in control under Nasdaq Marketplace Rule 5635(d) that may result from the potential issuance of securities in the non-public offerings.

---

| | | | |
|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** | **Broker Non-Votes** |
| 332920 | 116278 | 4459 | 1264352 |

---

***Proposal No. 9: Reverse Stock Split Proposal***

The stockholders approved an amendment to the Company's Certificate of Incorporation, as amended, at the discretion of the Company's board of directors, to effect a reverse stock split with respect to the Company's issued and outstanding shares of Common Stock, as well as stock held by the Company as treasury shares, at a ratio of 1-for-2 to 1-for-250 (the "Range"), with the ratio within such Range to be determined at the discretion of the Company's board of directors and included in a public announcement, subject to the authority of the Company's board of directors to abandon such amendment.

---

| | | | |
|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** | **Broker Non-Votes** |
| 1211478 | 491041 | 15490 |  |

---

***Proposal No. 10: Adjournment Proposal***

The stockholders approved the adjournment of the 2026 Annual Meeting to a later date, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of Proposal No. 3, Proposal No. 4, Proposal No. 5, Proposal No. 6, Proposal No. 7, Proposal No. 8, and/or Proposal No. 9. However, such an adjournment was not necessary in light of the approval of Proposal Nos. 3, 4, 5, 6, 7, 8 and 9 at the 2026 Annual Meeting.

---

| | | | |
|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** | **Broker Non-Votes** |
| 1228944 | 468211 | 20854 |  |

---

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit**<br> **Number** | **Description** |
| 10.1 | [First Amendment to bioAffinity Technologies, Inc. 2024 Incentive Compensation Plan](ex10-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **bioAffinity Technologies, Inc.** | **bioAffinity Technologies, Inc.** |
| Dated: April 30, 2026 | By: | */s/ Maria Zannes* |
|  |  | Maria Zannes |
|  |  | President and Chief Executive Officer |

---

## Exhibit 10.1

**Exhibit 10.1**

**FIRST AMENDMENT**

**TO**

**BIOAFFINITY TECHNOLOGIES, INC.**

**2024 EQUITY INCENTIVE COMPENSATION PLAN**

This First Amendment (this "<u>Amendment</u>") of the bioAffinity Technologies, Inc. 2024 Equity Incentive Plan (the "<u>Plan</u>") is effective as of April 30, 2026. All terms used but not defined herein shall have the meaning set forth in the Plan.

**<u>RECITALS</u>**

**WHEREAS,** the Board of Directors (the "<u>Board</u>") approved of the Amendment on January 15, 2026, and the Amendment was submitted to the holders of the outstanding stock of the Company (the "***Stockholders***") at the special meeting of the Company held on April 30, 2026, and such Stockholders have approved the adoption of this Amendment.

**<u>AGREEMENT</u>**

**NOW, THEREFORE,** the Plan is hereby amended as follows:

1. Section 4.1 of the Plan is hereby amended and restated as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1 <u>Share Limitation</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Subject to adjustment pursuant to Section 4.2 hereof, the maximum aggregate number of shares of Common Stock which may be issued under all Awards granted to Participants under the Plan shall be 1,000,000 shares, all of which may, but need not, be issued in respect of Incentive Stock Options.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Shares of Common Stock issued under the Plan may be either authorized but unissued shares or shares held in the Company's treasury. Any shares of Common Stock subject to Awards that are settled in Common Stock shall be counted against the maximum share limitations of this Section 4.1(a) as one share of Common Stock for every share of Common Stock subject thereto. To the extent that any Award under the Plan payable in shares of Common Stock is forfeited, cancelled, returned to, or repurchased by the Company for failure to satisfy vesting requirements or upon the occurrence of other forfeiture events, or otherwise terminates without payment being made thereunder, the shares of Common Stock covered thereby will no longer be counted against the foregoing maximum share limitations and may again be made subject to Awards under the Plan pursuant to such limitations. Shares of Common Stock that otherwise would have been issued upon the exercise of a Stock Option or Stock Appreciation Right or in payment with respect to any other form of Award, that are surrendered in payment or partial payment of the exercise price thereof and/or taxes withheld with respect to the exercise thereof or the making of such payment, will no longer be counted against the foregoing maximum share limitations and may again be made subject to Awards under the Plan pursuant to such limitations.